“There will be a ChatGPT moment for biotechnology, and if China gets there first, no matter how fast we run, we will never catch up,” the bipartisan Congressional commission said in the report, referring to the transformative chatbot released by U.S.-based OpenAI.
“Our window to act is closing. We need a two-track strategy: make America innovate faster, and slow China down,” the commission said. It recommends that the U.S. government spend at least $15 billion over the next five years to support the domestic biotech sector.
It’s weird how brazen this is - research shouldn’t be a competition, but even if it was this article would read like “we need to do two things to win this race: run faster, and kick all our opponents in the shins.” WE COULD BE COLLABORATING, YOU ASSHATS.
The US isn’t interested in collaboration, it wants control
Which is ultimately a self-defeating ambition, just a question of how much collateral damage gets done in the process.
the logic of capitalism
China’s biotech industry has evolved to the point that U.S. and European pharmaceutical giants in the last several months have spent billions to acquire China-developed drugs that could treat cancer if commercialized with regulatory approval. In March, British pharmaceutical giant AstraZeneca announced it will invest $2.5 billion in a research and development center in Beijing.
Uh oh
